Head-to-head evidence
BL-M11D1 vs Gemtuzumab Ozogamicin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Acute Myeloid Leukemia
Shared mechanism: CD33 · full Acute Myeloid Leukemia pipeline
BL-M11D1
Developed by SystImmune
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT05924750 (registry estimate)
Gemtuzumab Ozogamicin
Marketed by Pfizer
NCT00052299 · Phase 3 · completed
The trial was randomized and actively controlled, with 472 participants, but it was open-label rather than blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2026 · NCT05955261 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BL-M11D1's landscape · Gemtuzumab Ozogamicin's landscape